Camizestrant causes reversible pharmacological effects on retinal responses in rats.

ABSTRACT: Some patients treated with camizestrant in the SERENA-1 and SERENA-2 clinical trials experienced mild, transient, reversible visual effects. This nonclinical investigation used electroretinograms (ERGs) and mass spectrometry imaging to examine the effect of camizestrant on retinal responses in rats and to investigate the origin of the visual effects observed in humans. Mass spectrometry imaging was used to confirm the presence of camizestrant in the retina of rats following 7 consecutive days of dosing (75 mg kg^-1/day). A separate group of rats then received doses of either camizestrant (5, 12, 25, or 75 mg kg^-1/day) or control over 7 consecutive days. They were observed for 7 additional days without further dosing. ERGs were conducted at baseline, Days 1 and 7, and 7

SUBMITTER: Hamm G 

PROVIDER: S-EPMC12494933 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature